PatentVest released a report analyzing 20 muscle-preservation programs aimed at improving long-term obesity treatment outcomes by preserving lean muscle during GLP-1 therapy. The report highlights growing industry interest, strategic acquisitions by major pharma companies like Eli Lilly and AstraZeneca, and the potential for combination therapies to enhance patient results. This emerging category could reshape obesity treatment by improving body composition and creating new intellectual property and partnership opportunities. The report signals a shift from just weight loss to quality of weight loss in obesity therapeutics.
Novo Nordisk has regained competitive ground in the obesity market with the strong launch of its Wegovy pill, which outperforms Eli Lilly's Foundayo in new prescriptions due to better weight loss results and fewer drug interaction limits. Despite rec...
Eli Lilly announced it will present 16 abstracts at the 2026 Alzheimer's Association International Conference, highlighting new clinical evidence on Kisunla (donanemab-azbt), including long-term safety and biomarker data. The company also shared prom...
The Goldman Sachs Future Health Care Equity ETF (GDOC) gained momentum after positive news from its largest holding, Eli Lilly (LLY), whose price target was raised by JPMorgan. GDOC has returned 11.8% over the past three months, recovering from earli...
The weight loss drug market, driven by GLP-1 therapies, is expected to grow to $130-150 billion by 2035. The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors targeted exposure to this expanding sector, including major pharmaceutical c...
